Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Solid Malignant Neoplasm
99%
Malignant Neoplasm
96%
Pharmacokinetics
63%
Clinical Trial
62%
Gemcitabine
54%
Disease
51%
Adverse Event
47%
Pelareorep
46%
Chemotherapy
43%
Pancreas Adenocarcinoma
43%
Vorinostat
40%
Overall Survival
34%
Prostate Cancer
32%
Sorafenib
30%
Tolerability
30%
Progression Free Survival
28%
Anticarcinogen
28%
Pharmacodynamics
28%
Phase I Trials
27%
Metastatic Colorectal Cancer
27%
Drug Development
26%
Colorectal Carcinoma
26%
Hydroxychloroquine
24%
Phosphotransferase
23%
Immunotherapy
23%
Pevonedistat
23%
Chronic Myeloid Leukemia
23%
Pancreas Cancer
23%
Renal Cell Carcinoma
22%
Cisplatin
20%
Liver Cell Carcinoma
20%
Reoviridae
20%
Mammalian Target of Rapamycin Inhibitor
20%
Adenocarcinoma
19%
Mammalian Target of Rapamycin
19%
Paclitaxel
19%
Placebo
18%
Phosphotransferase Inhibitor
18%
Oncolytic Virus
18%
Phase II Trials
17%
Antitumor Activity
17%
Vasculotropin
17%
Nilotinib
17%
Biliary Tract Cancer
17%
Melanoma
17%
Pembrolizumab
16%
Oxaliplatin
16%
Sunitinib
15%
Mipsagargin
15%
Keyphrases
Advanced Solid Tumors
76%
Gemcitabine
50%
Apoptosis
48%
In Cancer
46%
Phase I Study
45%
Phase II Study
43%
Hepatocellular Carcinoma
42%
Vorinostat
40%
Pharmacokinetics
40%
Overall Survival
39%
Autophagy
34%
Cancer Patients
34%
Stable Disease
33%
Metastatic Colorectal Cancer (mCRC)
33%
Tolerability
33%
Tumor
33%
Phase I Clinical Trial
32%
Induced Apoptosis
32%
Sorafenib
31%
Solid Tumors
31%
Pelareorep
30%
Randomized Phase II Trial
30%
Chemotherapy
30%
Safety Profile
30%
Metastatic Pancreatic Ductal Adenocarcinoma
28%
Reolysin
28%
Prostate Cancer
28%
Phase II Trial
27%
Targeted Therapy
27%
Partial Response
26%
Malignancy
26%
Cancer Therapy
26%
Circulating Tumor Cells
25%
Chronic Myeloid Leukemia
25%
Radioembolization
25%
Median Overall Survival
25%
Drug Development
24%
Adverse Events
24%
Hydroxychloroquine
24%
Phase I Trial
23%
Pancreatic Cancer
23%
Alpha-fetoprotein
23%
TRAIL Receptors
23%
Aurora Kinase Inhibitor
23%
Anticancer Agents
22%
Antitumor Activity
21%
Dose-limiting Toxicity
21%
Nilotinib
20%
Reovirus
20%
Mammalian Target of Rapamycin (mTOR)
19%
Medicine and Dentistry
Overall Survival
44%
Prostate Cancer
40%
Neoplasm
39%
Hepatocellular Carcinoma
38%
Chemotherapy
34%
Radioembolization
32%
Pancreas Adenocarcinoma
31%
Cancer
28%
Metastatic Colorectal Cancer
27%
Targeted Therapy
25%
Diseases
24%
Arm
23%
Pelareorep
23%
Intraarterial Drug Administration
23%
Common Hepatic Artery
23%
Gemcitabine
19%
Clinical Trial
19%
Nilotinib
19%
Chronic Myelogenous Leukemia
19%
Cancer Therapy
16%
Sorafenib
16%
Pembrolizumab
16%
Cholangiocarcinoma
16%
Adverse Event
16%
Tumor Xenograft
15%
Glycon
15%
Vorinostat
15%
Castration Resistant Prostate Cancer
15%
Oncolytic Virus
15%
Circulating Tumor Cell
15%
Triple Negative Breast Cancer
15%
Alpha-Fetoprotein
15%
Scoring System
15%
Hydroxychloroquine
15%
Mesenchymal-Epithelial Transition
15%
Autophagy
15%
Pancreas Cancer
15%
Colorectal Carcinoma
15%
Epidermal Growth Factor Receptor
15%
Progression Free Survival
15%
Yttrium 90
14%
Tyrosine-Kinase Inhibitor
13%
Vasculotropin
12%
Cisplatin
12%
Tumor Immunity
11%
Imatinib
11%
Immunotherapy
11%
Surgery
10%
Cancer Cell
10%
Biological Product
10%